Clinical trials
Multiple Sclerosis, Primary Progressive clinical trials
Below are recruiting multiple sclerosis, primary progressive clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07759115Recruiting
Music program to improve thinking in people with multiple sclerosis
This study tests a music-based program to see if it can help improve thinking and memory in people with multiple sclerosis. It is a small feasibility study to see if the program is practical and helpful.
Austin, TexasAges 18–80 - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT02433028Recruiting
Long-term study for MS and related nervous system conditions
This is a long-term hospital study that follows people diagnosed with MS (and a few related conditions) to understand how disease changes over time. You may be asked to have regular check-ups, brain scans, and provide blood samples so researchers can track disease and treatment effects.
Aarau, Canton of AargauAges Any age - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59 - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07058896Recruiting
Improving walking skills in progressive multiple sclerosis
This study tests a program to help people with progressive multiple sclerosis who have severe walking difficulty. It aims to see if the program is feasible and can improve motor skills.
Ferrara, FEAges 18–75 - NCT07058870Recruiting
Improving walking skills in progressive multiple sclerosis
This study is testing a new way to help people with progressive multiple sclerosis improve their walking and motor skills. If you have mild to moderate trouble walking and meet some other health criteria, you may be able to join.
Ferrara, FEAges 18–75 - NCT05162638Enrolling by invitation
Immune study in MS and healthy adults using a special tube
This study compares immune (defense system) “profiles” between people with multiple sclerosis (MS) and healthy volunteers. It involves a thoracic duct cannulation procedure and several MRIs to see how immune cells behave and whether a specific immune pattern is different in MS.
Philadelphia, PennsylvaniaAges 18–40 - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+ - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT04650321RecruitingPhase 4
Home infusions of ocrelizumab for some people with MS
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Centennial, ColoradoAges 18–55 - NCT06062693Recruiting
Home Hand Training with Sensors for Better Dexterity
This study tests a new home-based hand training system using sensors to help improve hand movement and dexterity in people with Parkinson's, multiple sclerosis, or stroke. It also includes healthy volunteers for comparison.
LucerneAges 18–99 - NCT07852156Recruiting
Cooling during inpatient rehabilitation for people with multiple sclerosis
This trial tests whether cooling the body during a stay at a rehabilitation clinic helps people with multiple sclerosis (MS) feel better and recover more effectively. If you have MS and find that heat makes your symptoms worse, this study may help you manage your symptoms during rehab.
Valens, Canton of St. GallenAges 18 years+ - NCT05443633Recruiting
Brain and speech training for people with aphasia
This study looks at ways to improve language (speaking and understanding) for people with aphasia caused by stroke or dementia, using MRI to study brain function. It may help by testing language-focused approaches and how brain activity changes during treatment.
Tucson, ArizonaAges 21–80 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT06733922RecruitingPhase 4
Tracking MS changes with ofatumumab in active relapsing MS
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Calgary, AlbertaAges 18–99 - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Birmingham, AlabamaAges 18–65 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT03872102Recruiting
Brain imaging study to track Parkinson-related disease changes
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
Dallas, TexasAges Any age
Hear when a new Multiple Sclerosis, Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis, primary progressive?
- Yes. Clin2 currently lists 72 recruiting multiple sclerosis, primary progressive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis, primary progressive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis, primary progressive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Primary Progressive Aphasia
- Multiple Sclerosis (MS) - Relapsing-remitting
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.